Combination therapy: the risks of infection and tumor induction
Identifieur interne : 000E82 ( Istex/Curation ); précédent : 000E81; suivant : 000E83Combination therapy: the risks of infection and tumor induction
Auteurs : David E. Yocum [États-Unis]Source :
- Springer Seminars in Immunopathology [ 0344-4325 ] ; 2001-06-01.
Abstract
Summary: It is clear that the rate of infection is increased in most of the more serious forms of autoimmune disease and agents such as high-dose steroids and the alkylating agents increase this risk. Other agents such as MTX, CsA, LEF, AZA and the TNF antagonists do not appear to increase the risk of infection given either alone or in combination. Similarly, the risk of malignancy in certain types of autoimmune disease appears increased. However, other than the alkylating agents, none of the agents used appear to increase this risk. The more recently released agents such as CsA, LEF and the TNF antagonists need longer durations of follow-up to substantiate this, however. It is clear that, unless they are absolutely necessary, one should avoid the alkylating agents used either alone or in combination to avoid problems with infection and malignancy. In addition, the use of steroids should be kept as low as possible to avoid infections. It is possible that the use of the more benign agents alone and in combination earlier in the disease course may help to reduce both infection and the incidence of malignancy in the long run.
Url:
DOI: 10.1007/s002810100061
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E82
Links to Exploration step
ISTEX:1D22220BB1EED224C0993595E73B8373B4966997Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination therapy: the risks of infection and tumor induction</title>
<author><name sortKey="Yocum, David E" sort="Yocum, David E" uniqKey="Yocum D" first="David E." last="Yocum">David E. Yocum</name>
<affiliation wicri:level="1"><mods:affiliation>Arizona Arthritis Center, University of Arizona, 85724, Tucson, AZ, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Arizona Arthritis Center, University of Arizona, 85724, Tucson, AZ</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1D22220BB1EED224C0993595E73B8373B4966997</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1007/s002810100061</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-2ZRPLS7G-2/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E82</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E82</idno>
<idno type="wicri:Area/Istex/Curation">000E82</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Combination therapy: the risks of infection and tumor induction</title>
<author><name sortKey="Yocum, David E" sort="Yocum, David E" uniqKey="Yocum D" first="David E." last="Yocum">David E. Yocum</name>
<affiliation wicri:level="1"><mods:affiliation>Arizona Arthritis Center, University of Arizona, 85724, Tucson, AZ, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Arizona Arthritis Center, University of Arizona, 85724, Tucson, AZ</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Springer Seminars in Immunopathology</title>
<title level="j" type="abbrev">Springer Semin Immunopathol</title>
<idno type="ISSN">0344-4325</idno>
<idno type="eISSN">1432-2196</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="2001-06-01">2001-06-01</date>
<biblScope unit="volume">23</biblScope>
<biblScope unit="issue">1-2</biblScope>
<biblScope unit="page" from="63">63</biblScope>
<biblScope unit="page" to="72">72</biblScope>
</imprint>
<idno type="ISSN">0344-4325</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0344-4325</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Summary: It is clear that the rate of infection is increased in most of the more serious forms of autoimmune disease and agents such as high-dose steroids and the alkylating agents increase this risk. Other agents such as MTX, CsA, LEF, AZA and the TNF antagonists do not appear to increase the risk of infection given either alone or in combination. Similarly, the risk of malignancy in certain types of autoimmune disease appears increased. However, other than the alkylating agents, none of the agents used appear to increase this risk. The more recently released agents such as CsA, LEF and the TNF antagonists need longer durations of follow-up to substantiate this, however. It is clear that, unless they are absolutely necessary, one should avoid the alkylating agents used either alone or in combination to avoid problems with infection and malignancy. In addition, the use of steroids should be kept as low as possible to avoid infections. It is possible that the use of the more benign agents alone and in combination earlier in the disease course may help to reduce both infection and the incidence of malignancy in the long run.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000E82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:1D22220BB1EED224C0993595E73B8373B4966997 |texte= Combination therapy: the risks of infection and tumor induction }}
This area was generated with Dilib version V0.6.33. |